The features of reserpine-induced gastric mucosal lesions

Acta Pharmacologica Sinica

Volumn 31, Issue 8, 2010, Pages 938-943

  Ma, Xiu Juan ^a   Lu, Guo Cai ^a   Song, Shu Wei ^a   Liu, Wei ^a   Wen, Zhi Peng ^a   Zheng, Xiang ^a   Lü, Qian Zhou ^a,b   Su, Ding Feng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

compound hypotensive tablets; gastric mucosal lesions; reserpine; time course of recovery from gastric lesions; vagotomy

Indexed keywords

ANTIHYPERTENSIVE AGENT; COMPOUND HYPOTENSIVE TABLET; RESERPINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CONVALESCENCE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INDUCED DISEASE; DRUG SAFETY; HEART RATE; HYPERTENSION; INJURY SEVERITY; LOW DRUG DOSE; MALE; NONHUMAN; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SPONTANEOUSLY HYPERTENSIVE RAT; SPRAGUE DAWLEY RAT; STOMACH MUCOSA INJURY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ULCER HEALING; VAGOTOMY; VAGUS NERVE STIMULATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GASTRIC MUCOSA; HYPERTENSION; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; MALE; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; RESERPINE; TIME FACTORS;

EID: 77955438615     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.74     Document Type: Article

References (23)

1. Jia Q, Liu LP, Wang YJ. Stroke in China. Clin Exp Pharmacol Physiol 2010; 37: 259-264
2. Luepker RV, Arnett DK, Jacobs DR Jr, Duval SJ, Folsom AR, Armstrong C, et al. Trends in blood pressure, hypertension control, and stroke mortality: the Minnesota Heart Survey. Am J Med 2006; 119: 42-49
3. Bansal D, Chahoud G, Smith ES, Mehta JL. Prevention of heart failure. Curr Opin Cardiol 2006; 21: 510-516
4. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens 2008; 26: 1477-1486
5. Zoungas S, Asmar RP. Arterial stiffness and cardiovascular outcome. Clin Exp Pharmacol Physiol 2007; 34: 647-651
6. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 356: 1955-1964
7. Sheldon MB, Kotte JH. Effect of rauwolfa serpentina and reserpine on the blood pressure in essential hypertension: a long-term double-blind study. Circulation 1957; 16: 200-206
8. Finnerty FA Jr, Kakaviatos N, Chupkovich V. Value of chlorthalidone plus reserpine in moderately severe and severe hypertension: A two-year study. Circulation 1965; 32: 13-18
9. Dillon D, Swain JM. Gastro-intestinal hemorrhage as a complication of reserpine administration: report of two cases. Am J Psychiatry 1956; 113: 462-463
10. Locket S. Oral preparations of Reuwolfa serpentina in treatment of essential hypertension. Br Med J 1955; 1: 809-816
11. Bulpitt CJ, Dollery CT. Side effects of hypotensive agents evaluated by a self administered questionnaire. Br Med J 1973; 3: 485-490
12. Sandor V, Cuparencu B. Analysis of the mechanism of the protective activity of some sympathomimetic amines in experimental ulcers. Pharmacology 1977; 15: 208-217
13. Yamaguchi Y, Hirio J, Puke H, Kumada S. Mechanism of gastric secretagogue effect of reserpine in rats. J Pharmacol Exp Ther 1978; 205: 710-717
14. Kim KS, Shore PA. Mechanism of action of reserpine and insulin on gastric amines and gastric acid secretion, and the effect of monoamine oxidase inhibition. J Pharmacol Exp Ther 1963; 141: 321-325
15. Gamberini MT, Skorupa LA, Souccar C, Lapa AJ. Inhibition of gastric secretion by a water extract from Baccharis triptera, Mart. Mem Inst Oswaldo Cruz 1991; 86 Suppl 2: 137-139
16. Ma XJ, Shen FM, Liu AJ, Shi KY, Wu YL, Su DF. Clonidine, moxonidine, folic acid, and mecobalamin improve baroreflex function in stroke-prone, spontaneously hypertensive rats. Acta Pharmacol Sin 2007; 28: 1550-1558
17. Zheng RM, Zou CJ, Zhu SG. p38 MAPK mediates cardiovascular and behavioral responses induced by central IL-1 beta and footshock in conscious rats. Acta Pharmacol Sin 2004; 25: 266-270
18. Li HL, Kang YM, Yu L, Xu HY, Zhao H. Melatonin reduces blood pressure in rats with stress-induced hypertension via GABAA receptors. Clin Exp Pharmacol Physiol 2009; 36: 436-440
19. Yalcin M, Aydin C. Cardiovascular effects of centrally administered arachidonic acid in haemorrhage-induced hypotensive rats: investigation of a peripheral mechanism. Clin Exp Pharmacol Physiol 2009; 36: 447-453
20. Wang JL, Wang L, Wu ZT, Yuan WJ, Su DF, Ni X, et al. Low dose of mox-onidine within the rostral ventrolateral medulla improves the barore-fex sensitivity control of sympathetic activity in hypertensive rat. Acta Pharmacol Sin 2009; 30: 1594-1600
21. Onoma M, Yogo K, Ozaki K, Kamei K, Akima M, Koga H, et al. Oral mitemcinal (GM-611), an erythromycin-derived prokinetic, accelerates normal and experimentally delayed gastric emptying in conscious dogs. Clin Exp Pharmacol Physiol 2008; 35: 35-42.
22. Wang XQ, Zhang HG, Cheng YQ, Li XH. Inhibition of left ventricular remodelling in spontaneously hypertensive rats by G alpha q-protein carboxyl terminus imitation polypeptide GCIP-27 is not entirely dependent on blood pressure. Clin Exp Pharmacol Physiol 2008; 35: 1215-1221
23. Krug S, Zhang Y, Mori TA, Croft KD, Vickers JJ, Langton LK, et al. N-Acetylcysteine prevents but does not reverse dexamethasone-induced hypertension. Clin Exp Pharmacol Physiol 2008; 35: 979-981